Retinal neovascularization developing secondary to ischemic branch retinal vein occlusion (BRVO) is conventionally treated with sector panretinal photocoagulation (PRP). Elevated levels of the vascular endothelial growth factor (VEGF) play an important role in the development of these new vessels\[[@ref1]\] and thus administration of anti-VEGF agents has been reported to be of therapeutic use as well.\[[@ref2][@ref3]\] We present a case of BRVO in a 55-year-old female, previously treated with PRP that had persistent neovascularization that was treated with a single anti-VEGF injection. The authors report the use of optical coherence tomography-angiography (OCT-A) as a noninvasive imaging platform to demonstrate its value in diagnosing retinal neovascularization and treatment response following anti-VEGF injection \[[Fig. 1](#F1){ref-type="fig"}\].

![Optical coherence tomography angiography scans. Retina slab (6 × 6 mm) fovea centered (a) and 8 mm × 8 mm (b) inferior to the macula demonstrated profound capillary nonperfusion in the inferotemporal quadrant (star). Morphology of the retinal neovascularization; that is large frond of abnormal vasculature (bold arrow) and terminal loops of irregular proliferation of small-caliber new vessels (small arrows) called as exuberant vascular proliferation (EVP) are seen. 4 weeks postbevacizumab injection showed pruning of new vessel (bold arrow) with dramatic reduction in the EVP (small arrow) (c and d)](IJO-66-572-g001){#F1}

Conclusion {#sec1-2}
==========

Intravitreal injection of anti-VEGF achieved short-term reduction of leakage from persistent active neovascularization (NVE) with ischemic BRVO as demonstrated using noninvasive OCT-A.
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